Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Status:
Terminated
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
The aim of this study is to analyze if administration of conestat alfa for 72 hours in
addition to standard of care (SOC) in patients hospitalized with non-critical SARS-CoV-2
pneumonia (WHO Ordinal Scale Score 3 or 4) reduces the risk of disease progression to Acute
Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).